Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.
cardiovascular disease
hypertension
mortality
renal hemodynamics
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
22
12
2018
accepted:
15
05
2019
pubmed:
22
7
2019
medline:
28
4
2020
entrez:
21
7
2019
Statut:
ppublish
Résumé
The Systolic BP Intervention Trial (SPRINT) found that intensive versus standard systolic BP control (targeting <120 or <140 mm Hg, respectively) reduced the risks of death and major cardiovascular events in persons with elevated cardiovascular disease risk. However, the intensive intervention was associated with an early decline in eGFR, and the clinical implications of this early decline are unclear. In a About 10.3% of the 4270 participants in the intensive group had a ≥20% eGFR decline versus 4.4% of the 4256 participants in the standard arm ( Although intensive systolic BP lowering resulted in greater early decline in eGFR, there was no evidence that the reduction in eGFR owing to intensive systolic BP lowering attenuated the beneficial effects of this intervention on cardiovascular events or all-cause mortality.
Sections du résumé
BACKGROUND
The Systolic BP Intervention Trial (SPRINT) found that intensive versus standard systolic BP control (targeting <120 or <140 mm Hg, respectively) reduced the risks of death and major cardiovascular events in persons with elevated cardiovascular disease risk. However, the intensive intervention was associated with an early decline in eGFR, and the clinical implications of this early decline are unclear.
METHODS
In a
RESULTS
About 10.3% of the 4270 participants in the intensive group had a ≥20% eGFR decline versus 4.4% of the 4256 participants in the standard arm (
CONCLUSIONS
Although intensive systolic BP lowering resulted in greater early decline in eGFR, there was no evidence that the reduction in eGFR owing to intensive systolic BP lowering attenuated the beneficial effects of this intervention on cardiovascular events or all-cause mortality.
Identifiants
pubmed: 31324734
pii: ASN.2018121261
doi: 10.1681/ASN.2018121261
pmc: PMC6683716
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1523-1533Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000439
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL145494
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000005
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000073
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118219
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000003
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025752
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR011234
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900040C
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024134
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900049C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900046C
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025764
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000105
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000075
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103337
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000064
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900047C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000050
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002003
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025755
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000433
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000093
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200900048C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000002
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK106574
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001064
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003142
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025771
Pays : United States
Informations de copyright
Copyright © 2019 by the American Society of Nephrology.
Références
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Epidemiology. 1992 Mar;3(2):143-55
pubmed: 1576220
Arch Intern Med. 2005 Apr 25;165(8):923-8
pubmed: 15851645
Epidemiology. 2009 Nov;20(6):880-3
pubmed: 19829187
Lancet. 2010 Jun 12;375(9731):2073-81
pubmed: 20483451
Kidney Int. 2011 Jun;79(12):1331-40
pubmed: 21289598
Kidney Int. 2011 Aug;80(3):282-7
pubmed: 21451458
Lancet. 2014 May 31;383(9932):1899-911
pubmed: 24881994
Clin Trials. 2014 Oct;11(5):532-46
pubmed: 24902920
JACC Heart Fail. 2015 Mar;3(3):214-23
pubmed: 25742759
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272
Circulation. 2016 Feb 9;133(6):584-91
pubmed: 26762524
JAMA. 2016 Jun 28;315(24):2673-82
pubmed: 27195814
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
J Am Soc Nephrol. 2017 Feb;28(2):671-677
pubmed: 27516235
Kidney Int. 2017 Mar;91(3):683-690
pubmed: 27927602
J Am Soc Nephrol. 2017 Sep;28(9):2794-2801
pubmed: 28473636
J Am Soc Nephrol. 2017 Sep;28(9):2812-2823
pubmed: 28642330
Ann Intern Med. 2017 Sep 19;167(6):375-383
pubmed: 28869987
Am J Kidney Dis. 2018 Mar;71(3):352-361
pubmed: 29162340
Lancet Diabetes Endocrinol. 2018 Jul;6(7):555-563
pubmed: 29685860
Kidney Int. 1997 Mar;51(3):793-7
pubmed: 9067912